Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study purpose is to evaluate baseline clinical data, outcome after front-line Rituximab containing chemotherapy and survival in patients with grade 3b Follicular Lymphoma.
Also an histological central review is planned in order to re-assess baseline diagnosis according to new 2016 World Health Organization (WHO) criteria.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall Response Rate | Number of patients who achieve Complete Response or Partial Response after treatment | End of front-line treatment (evaluated from diagnosis up to 30 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Progression Free Survival | Time from last response to nearest relapse or follow-up | From first response to last follow-up for at least 2 years (up to 15 years) |
| Overall Survival | Time to last follow-up or death |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Adult patient with grade 3b Follicular Lymphoma treated with Rituximab containing chemotherapy as front-line treatment
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Barbara Botto, MD | Contact | +390116334553 | bbotto@cittadellasalute.to.it |
| Name | Affiliation | Role |
|---|---|---|
| Barbara Botto, MD | A.O.U. Città della Salute e della Scienza | Principal Investigator |
Not provided
paper publication
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Date of last follow-up for at least 2 years (up to 15 years) |